By the mid 1980's, it was clear that the transforming activity of oncogenic Src was linked to the activity of its tyrosine kinase domain and attention turned to identifying substrates, the putative next level of control in the pathway to transformation. Among the first to recognize the potential of phosphotyrosine-specific antibodies, Parsons and colleagues launched a risky shotgun-based approach that led ultimately to the cDNA cloning and functional characterization of many of today's best-known Src substrates (for example, p85-Cortactin, p110-AFAP1, p130Cas, p125FAK and p120-catenin). Two decades and over 6000 citations later, the original goals of the project may be seen as secondary to the enormous impact of these protein substrates in many areas of biology. At the request of the editors, this review is not restricted to the current status of the substrates, but reflects also on the anatomy of the project itself and some of the challenges and decisions encountered along the way.
INTRODUCTION
The decade of the 1980's witnessed an immense leap in the understanding of oncogenic signaling, including that mediated by v-Src, the first identified oncoprotein 1 and the first described protein tyrosine kinase (PTK). 2 The discovery of Src as a PTK was quickly followed by identification of other oncogenic PTKs 3, 4 including members of the receptor tyrosine kinase family, and attention turned to the possibility of downstream effectors. The search for receptor tyrosine kinase substrates was facilitated by the ligand-induced formation of stable receptor-substrate complexes that could be immunoprecipitated for analysis. In contrast, the substrates of Src were slow to emerge owing primarily to technical constraints. Nonetheless, by mid-decade it was clear that the kinase activity of Src was essential for its transforming activity and the possibility of a substrate-dependent pathway to transformation was increasingly difficult to ignore.
Lacking the handle provided by today's phosphotyrosinespecific antibodies, identifying putative Src substrates was a slow and labor-intensive process, requiring high-level 32 P-labeling of Src-transformed cells, separation of the radiolabelled phosphoproteins by 2-D polyacrylamide gel electrophoresis and an in-gel alkaline treatment protocol designed to leave phosphotyrosine residues intact, while cleaving phospho-serine and -threonine. It was largely ineffective and by 1988, only a handful of putative substrates had been identified (for example, b1-integrin, talin, vinculin, phosphatidylinositol-3 kinase, p36 (calpactin) and p42 (later, identified as MAP kinase)). 5 The technical problems were ultimately resolved by the discovery of phosphotyrosine (pTyr)-specific antibodies, 6 which provided a convenient and highly specific molecular handle on pTyr-containing proteins. For the first time, tyrosinephosphorylated proteins could be selectively immunoprecipitated and/or visualized by western blotting. The technology was rapidly adopted by Parsons and colleagues in the form of a risky endeavor that led ultimately to the cDNA cloning and functional characterization of several of today's best-known Src substrates. Contrary to expectations, most shared an ability to regulate the actin cytoskeleton, as exemplified by the roles of FAK and p120 in cell-ECM and cell-cell adhesion, respectively. They were, in fact, among the first representatives of a larger network of substrates that now define one of the better-recognized roles of c-Src.
At the request of the editors, this review is not entirely about the substrates, but reflects also on the anatomy of the project itself and some of the challenges and decisions encountered along the way. Indeed, despite the enormous long-term impact of the work described below, it was not at all obvious at the time that the spectrum of apparent Src targets, as indicated by pTyrantibodies, would turn out to be anything more than a collection of physiologically irrelevant proteins, phosphorylated unproductively by an overexpressed and promiscuous kinase. Arguing against that notion was the apparent specificity implied by the recognition of just 15-20 well-defined pTyr substrates from a proteome of some 30 000 candidates.
The search for Src substrates In 1987, postdoctoral fellows Kanner and Reynolds, together with Parsons, initiated a high-risk project (never subjected to NIH peer review) to identify the Src substrates indicated by pTyr-Abs. The two-pronged strategy was to first use pTyr-antibodies to purify the tyrosine-phosphorylated proteins from Src-transformed cell lysates, with the aim to shotgun immunize mice for generation of monoclonal antibodies (mAbs) to individual substrates. The substrates were then to be identified directly by cDNA cloning, using the mAbs to screen lGT11 expression libraries.
Accordingly, tyrosine-phosphorylated proteins were purified from cell lysates of Src-transformed chicken embryo fibroblasts, essentially in one step, using anti-pTyr immunoaffinity chromatography. 7 Given the small amount of purified protein available, only four mice were immunized, two of which responded robustly to the chicken-derived antigens. As there was almost no information on substrate abundance, direct and indirect ELISAs were developed, the former for robustness, the latter providing increased sensitivity. 8 Both mice were fused, generating 786 hybridomas, of which 251 were positive in one or both of the ELISA assays. After subcloning and biochemical validation, the final tally came to 32 individual mAbs recognizing seven distinct tyrosine-phosphorylated substrates, and in a few cases, pTyr itself. 8 To isolate the corresponding cDNAs efficiently, lGT11 libraries were initially screened with an antibody pool comprised of the best mAbs to each substrate. The positive clones were then rescreened with each individual antibody, resulting in partial cDNA clones for most substrates, the lone exception being p120 (as described elsewhere). Because of the rapid expansion in the scope of the project, it was broken up according to substrate (along with corresponding mAbs and partial cDNAs), and redistributed to lab members to be completed as independent projects.
Interestingly, sequencing of the open reading frames revealed that all but tensin encoded entirely novel genes. Moreover, with the possible exception of p185, which was not pursued, all of the proteins were ultimately validated as physiologically relevant Src substrates. Notably, an unexpected finding at the time of original sequencing was the almost ubiquitous presence of one or more Src homology domains (for example, SH1, SH2 and SH3). For example, FAK itself emerged as an unconventional PTK (that is, SH1 domain), tensin was the first reported example of an SH2 domain in a cytoskeletal protein, and both Cortactin and p130CAS contained SH3 domains. P120, on the other hand, was similar to b-catenin, as both proteins contained central Armadillo Repeat Domains. P120 was initially viewed as an outlier based on the lack of PTK-associated domains. However, both p120 and b-catenin are prominent Src substrates that together control the dynamic interface between classical cadherin complexes and the actin cytoskeleton. Importantly, they bind and regulate all 26 members of the human classical cadherin family, thereby accounting for substantial control over cell-cell adhesion systems in essentially all solid tissues. Thus, despite distinctly different roles, all of the substrates share close functional connections to the actin cytoskeleton.
The substrates are now well known and firmly established in the literature. The following sections contain brief accounts of progress to date for each of the five novel substrates ( Table 1) . As they were discovered as part of a larger effort to understand the mechanism(s) underlying transformation by Src, each section at least briefly reflects on the nature of that relationship.
However, a much better measure of the importance of the substrates stems from their enormous impact over the past two decades in areas of biology that extend well beyond the early focus on Src.
P85/CORTACTIN
Early work with p85 revealed striking localization to the cortical actin cytoskeleton, giving rise to the name 'cortactin'. 9 On western blots, cortactin appeared as two to three bands ranging from 80-85 kDa, all of which were phosphorylated on tyrosine by Src. Early work in several cell types revealed that cortactin is also tyrosine-phosphorylated by other Src-family members and following ligand activation of the FGF receptor. 10 
Structure
Cortactin was described well ahead of the other substrates due largely to the rapid isolation of a full-length cDNA clone. 11 Sequence analysis revealed a novel amino-terminal domain consisting of six-and-one-half 37 amino-acid tandem repeats, later identified as the actin-binding region, and a carboxy-terminal SH3 domain. The human ortholog (EMS1) was cloned shortly thereafter as a component of the 11q13 amplicon in head and neck squamous cell carcinoma (HNSCC). 12 Cellular function and effects of phosphorylation Consistent with a role in cortical actin regulation, cortactin promotes actin polymerization through direct binding to the actin related protein (Arp)2/3 complex [13] [14] [15] and interactions with the Arp2/3 nucleation activator protein, neuronal Wiskott-Aldrich Syndrome protein (N-WASp). 16, 17 Cortactin also stabilizes binding of Arp2/3 to F-actin networks, consistent with its function in lamellipodia dynamics. [18] [19] [20] Studies conducted with the N-WASp activating proteins WIP and Nck1 demonstrate that tyrosine phosphorylation of cortactin enhances Arp2/3 activation through binding of the adaptor protein Nck1, which in turn activates N-WASp directly or through the association of the cortactin-Nck1 complex with WIP. 21 Further work on invadopodia formation confirmed that Nck1 binding to cortactin is critical for promoting cytoplasmic N-WASp-mediated Arp2/3 actin nucleation. 22, 23 These observations indicate a positive role for Src-mediated cortactin phosphorylation in regulating Arp2/3-based actin filament formation.
Changes in cellular actin filament polymerization are hallmarks of Src-transformation and cortactin is well positioned to regulate these changes. Invadosomes (aka, podosomes and invadopodia), 14 comprise another hallmark of cancer found in most carcinoma cell types, where they direct proteolytic degradation of the underlying basement membrane, thereby facilitating local tumor cell spread. 24, 25 Cortactin expression and Src-based phosphorylation are essential for invadosome formation and Regulation of cell-cell adhesion by classical cadherins Regulation of cell-cell contacts
The five substrates identified during the course of this study, their cellular function and potential role in Src-directed transformation.
Substrates of Src AB Reynolds et al function, 22, 26, 27 suggesting that tyrosine phosphorylation of cortactin is a critical regulator of the early metastatic cascade. Indeed, cortactin is now a widely accepted marker for invadosomes and may have a role in regulating the dynamic changes in actin polymerization required for invadopodia function in transformed cells.
Mouse models and human disease Interestingly, embryo formation was blocked by constitutive cortactin knockout (using gene trap technology) due to mislocalization of the Arp2/3-F-actin network and inability of the oocyte to undergo proper asymmetric cell division. 28 In adult mice, however, the effect of global disruption of the gene (induced by Cre-lox activation) was relatively mild, the main phenotype being increased vascular permeability. A possible explanation for the discrepancy is that expression of the aminoterminal end of cortactin by the gene trap vector may have a dominant-negative affect, as apposed to the null phenotype associated with the conditional knockout.
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EMS1 amplification occurs in multiple carcinoma types, suggesting a role for cortactin in human malignancy. 30 In HNSCC, increased copy number correlates with poor patient survival, increased recurrence and lymph node involvement. 31, 32 In premalignant HNSCC lesions, EMS1 overexpression associates with progression to malignancy. 33 Other effects of ems1 gene amplification in HNSCC include increased invasive disease, Arp2/3 activation, invadopodiaassociated matrix degradation, metalloproteinase secretion and resistance to targeted therapeutics and radiation. [34] [35] [36] [37] These observations suggest a prominent role for cortactin amplification and/or overexpression in HNSCC.
P110/AFAP1
p110/AFAP1 (formerly AFAP-110) was initially identified as a 110-kDa tyrosine-phosphorylated protein that bound to activated forms of Src in an SH3-and SH2-dependent fashion. 7, 8, 38 Immunofluorescence analysis of normal cells revealed an association with stress filaments and the cortical actin matrix, giving rise to the name 'AFAP-110' (actin filament-associated protein 110 kDa). 8, 38 It was later re-named 'AFAP1' (actin filament-associated protein-1) by the Human Genome Project to distinguish it from newly discovered family members AFAP1L1 (AFAP1-like 1) and AFAP1L2 (AFAP1-like 2). 39, 40 Structure cDNA library screening initially led to the discovery of the neuronal form of AFAP1, a 120-kDa protein called AFAP-120 expressed exclusively in neurons. 41 Further screening turned up the fibroblast form of AFAP1, which lacks just one codon relative to the neuronal form. 42 Structure-function analyses revealed an actin filament binding motif in the AFAP1 carboxy-terminus, 43, 44 preceded by a series of protein-binding modules, including 2 pleckstrin homology domains, one of which binds to the protein kinase C (PKC) isoforms a, b, g and l. AFAP1 also contained SH2-binding motifs (generated by Src phosphorylation) and an SH3-binding motif that facilitates stable interactions with Src, as well as the Src-family members Fyn and Lyn. 41, 45 These data indicate that AFAP1 may function by bridging interactions between Src-family kinases and the actin cytoskeleton.
Cellular function and effects of phosphorylation In addition to direct interactions with actin filaments, AFAP1 can multimerize via a carboxy-terminal leucine motif 43, 44 to function as an actin filament cross-linking protein. Deletion of this motif reduces multimer size, and induces a transition from cortical fibers to tighter actin filament bundles. The ability of AFAP1 to affect dynamic changes in actin filament cross-linking is regulated by PKCa-mediated phosphorylation, which modulates the conformation and multimer size of AFAP1 in a fashion analogous to deletion of the Lzip motif. 44 Thus, AFAP1 mediates dynamic changes in actin filament cross-linking in response to PKCa phosphorylation.
Interestingly, several lines of evidence suggest that AFAP1 can function as an upstream activator of Src. For example, deletion of the AFAP1 Lzip motif enables autonomous activation of c-Src in cells. 46 In a potentially analogous scenario, PKCa can promote Src activation by an AFAP1-dependent mechanism. Overall, the data suggest that AFAP1 phosphorylation by PKCa induces structural changes (for example, destabilization of AFAP1 multimers) that potentiate both its actin-filament cross-linking activity and its positive effects on c-Src. [47] [48] [49] [50] A working model based on these data proposes that the Lzip motif functions as an auto inhibitor of AFAP1 activity by stabilizing the multimeric configuration, a condition relieved by upstream activation of PKCa. Notably, AFAP1 knockdown has little effect on the Src-transformation phenotype. Thus, AFAP1 is apparently an upstream effector of c-Src, but its role downstream of activated Src, does not modulate transformation.
Mouse models and human cancer To date, AFAP1 has not been extensively investigated with regard to potential roles in human cancer. Its expression, however, is significantly elevated in at least two cancers, namely cancer of the prostate and neuroblastoma. 51, 52 Together, these data indicate that AFAP1 may be positioned to promote cancer progression, possibly through its function as a signaling protein or as a regulator of cytoskeletal integrity and cell contractility. Its role as a c-Src activating protein and regulator of stress filament crosslinking in tumor formation in mouse models has not been determined. The establishment of mouse models will be important to determine a role for AFAP1 in cancer progression. Early results indicate that AFAP1 knockout mice appear to have deficits in lactation, indicating AFAP1's normal function could have an important role in breast physiology (Cho, Flynn and Cunnick, manuscript in preparation). This mouse model may also be a useful tool to determine a role for AFAP1 in tumor formation or tumor progression.
P130CAS (CAS)
Of the 15-20 Src substrates evident on the original pTyr western blots, p110 (AFAP1) and p130Cas (Cas) were singled out because it strongly coimmunoprecipitated with Src, a potential indicator of physiological relevance. 8, 38, 53 The p130 interaction turned out to be dependent on the Src SH2 domain, suggesting an SH2-mediated interaction with a phosphotyrosine epitope on p130. This same p130 protein also associated with the v-Crk oncoprotein (p47v-Crk). The p130 cDNA was later cloned by Hirai et al., 54 who proposed the name p130Cas for 'Crk-associated substrate'. Structure Analysis of the amino-acid sequence of p130Cas (Cas) predicted a unique domain structure consisting of an amino-terminal SH3 domain and a centrally located 'substrate-binding domain' containing 15 Tyr-X-X-Pro motifs hypothesized to serve as binding sites for the Crk SH2 domains when phosphorylated. The carboxyterminus contained an additional predicted Src SH2 domainbinding site and an adjacent poly-proline motif likely to function as an SH3 domain-binding site for Src. 55 Analysis of the dynamic interaction between Src and Cas led to a novel paradigm of processive binding between Src and its substrates, whereby the kinase forms an initial, lower affinity interaction with the substrate (in this case via the Cas SH3 domain) before enzymatic modification of the substrate. 56, 57 Ensuing phosphorylation of the adjacent tyrosine residue on Cas then provides a binding site for the Src SH2 domain, significantly strengthening the interaction between the two proteins. 55 A similar model was predicted for AFAP1, whereby SH3-directed interactions were required for tyrosine phosphorylation of AFAP1 and high-affinity binding with Src. 58, 59 Binding of Cas to the c-Src SH3 domain also results in release of c-Src's autoinhibitory conformation resulting in activation of the kinase. 39, 56, [60] [61] [62] Thus, as with AFAP1, p130Cas can function as an upstream activator of c-Src. Cas is now recognized as the prototype of a four-member family of adaptor/ scaffolding proteins that share common structural and functional features. [63] [64] [65] [66] In addition, to Cas (also known as BCAR1 for breast cancer anti-estrogen resistance-1), this family includes NEDD9 (also known as HEF1 and Cas-L), EFS (also known as Sin) and CASS4 (also known as HEPL).
Cellular function and effects of phosphorylation As with several of the other Src substrates discussed in this review, Cas becomes phosphorylated in response to integrin engagement, localizes to focal adhesions and has a critical role in adhesiondependent cytoskeletal remodeling and cell migration. [67] [68] [69] [70] [71] [72] These activities are mediated by the processive phosphorylation of tyrosine residues located in the Cas substrate-binding domain and subsequent association with Crk, leading to activation of Rac1 and Rap1. [73] [74] [75] Cas-Crk coupling may also contribute to its function as a mechanotransducer, as Cas phosphorylation is significantly enhanced under conditions in which the Cas substratebinding domain is physically stretched in response to integrin engagement. 76 Cas signaling is involved in the regulation of cell death once apoptosis has been triggered, which is mediated by a 31-kDa carboxy-terminal Cas fragment produced by the action of apoptosis-induced proteases. 77, 78 Independent expression of the 31 kDa fragment causes diverse pro-apoptotic cellular activities.
In addition to adhesion signaling, Cas has been implicated in the control of cell proliferation and survival. Cas tyrosine phosphorylation is induced in response to a number of mitogenic stimuli. 79, 80 However, the mechanisms by which Cas phosphorylation regulates cell proliferation are complex and not yet clear. Cas becomes dephosphorylated on tyrosine and phosphorylated on serine/threonine residues during mitosis, which leads to disruption of Cas/FAK/c-Src interactions and dissolution of focal adhesions. 81 These changes in phosphorylation may enable Cas to affect dynamic changes in focal adhesions in response to phosphorylation by Src and subsequent dephosphorylation.
Mouse models and human disease Mouse models of breast tumorigenesis further support a role for Cas in cell proliferation and survival, as mammary gland-specific overexpression of Cas results in tissue hyperplasia coincident with Src and Akt activation. 82 Furthermore, when crossed with a HER2-neu mammary tumor model, Cas overexpression results in shortened tumor latency, while knockdown of Cas in cells isolated from HER2-neu tumors results in increased apoptosis. 82 As an integral component of signaling pathways that control cytoskeletal dynamics, adhesion, migration, proliferation, survival and apoptosis, Cas expression positively correlated with poor prognoses in a number of human cancers, including breast, prostate, ovarian and lung. 65, [83] [84] [85] [86] [87] [88] It remains undetermined whether these pathological states are a direct consequence of Cas function and, if so, whether specific Cas signaling nodes can be targeted as a means of disease management. Nonetheless, Cas has clearly shown an ability to enhance cell proliferation and survival. For example, overexpression of Cas in breast cancer cells can result in a failure to undergo cell cycle arrest and apoptosis in response to antiestrogens and cytotoxic agents. 84, 89, 90 The ability of Cas to bind to, and activate, c-Src 62, 91, 92 has an important role in this resistance pathway 89, 90 demonstrating a clear link between Cas, Src and cell survival.
FOCAL ADHESION KINASE, P125FAK (FAK)
Early studies demonstrated that in normal chick embryo fibroblast cells, the only major substrate phosphorylated on tyrosine was a single 125 kDa phosphoprotein. 93 A hint regarding the function of p125 came from observations that levels of phosphotyrosine increased in integrin-dependent adhesion structures upon attachment of cells to fibronectin, 94 crosslinking cell surface integrins 95 or platelet activation and adhesion to fibrinogen. 96 Structure Identification of the p125 protein elicited excitement during the early phases of this project. At that time, BLAST databases came into use and early identification of coding sequences revealed that p125 was a tyrosine kinase. Further, studies by other colleagues in the field demonstrated that integrin engagement was associated with increased tyrosine phosphorylation in focal adhesion complexes. With p125 thought to have a role in regulating integrin engagement and signaling, the lab gave much thought into naming the protein, ultimately deciding on focal adhesion kinase (FAK), due to its colocalization with focal adhesion complexes and intrinsic kinase activity. The observation that FAK localized to regions of the cell that closely adhere to the extracellular matrix indicated that it might function in the transduction of biochemical signals both in response to and in the control of cell adhesion. 97 The domain organization of FAK consists of a FERM (Band Four.one/Ezrin/Radixin/Moesin) domain, catalytic domain, a domain of unknown structure containing several proline-rich regions and a C-terminal domain that mediates localization (the focal adhesion targeting domain). 98 Cellular function and effects of phosphorylation Tyrosine 397 is a major site of phosphorylation in FAK and has a critical role in signaling as a docking site for SH2 domaincontaining proteins, including Src. 97, 99 The relationship between FAK and cell adhesion is complex. Integrin-dependent cell adhesion to extracellular matrix proteins stimulates FAK activity resulting in tyrosine phosphorylation on multiple residues. 98 FAK controls a number of biological responses regulated by cell adhesion, including anoikis, proliferation and cell migration. One role of FAK in the control of cell migration is the regulation of the assembly and disassembly of focal adhesions, adhesive structures that tether cells to the underlying extracellular matrix. [100] [101] [102] FAK mutants that cannot be phosphorylated at tyrosine 397 are defective for disassembly of cell/matrix adhesions. In this regard, Src is likely an important signaling partner for FAK, as Src null cells exhibit a similar phenotype. 102 FAK regulates cell adhesion through multiple mechanisms. The FAK/Src complex controls phosphorylation and the activity of PIP5KCI, an isoform of phosphatidylinositol 5 0 kinase that discretely localizes to cell/extracellular matrix adhesions, regulates the generation of PI(4,5)P2 at these sites, and the subsequent assembly of these structures. 103 FAK can also regulate cell adhesion through Rho family GTPases. [104] [105] [106] [107] [108] The focal adhesion targeting domain of FAK mediates binding to two focal adhesionassociated proteins, paxillin and talin, and each has been implicated in directing FAK localization to focal adhesions and in the regulation of cell adhesion. 109, 110 Paxillin had been identified as a Src substrate by Glenney et al. 111 FAK can directly and indirectly (via Src) promote paxillin phosphorylation on tyrosine.
Like FAK, paxillin is required for proper turnover of cell/matrix adhesions and mutants of paxillin that are defective for tyrosine phosphorylation are defective for regulation of adhesion turnover. 102 The interaction of FAK and talin is also important. FAK is required for the recruitment of talin to nascent focal adhesions but not to mature focal adhesions; 112 Talin has a role in recruiting or stabilizing FAK in mature adhesions. The interaction between FAK and talin 113 could offer another mechanism for regulating adhesion. Further, FAK may regulate the cleavage of talin by calpain, which is an important mechanism for regulation of adhesion. 112, 114 p85-Cortactin also binds via its SH3 domain to two proline-rich sequences in the C-terminal domain of FAK. Mutation of these sites in FAK impairs its ability to regulate cell/ matrix adhesion turnover. 115 Although these sequences mediate interaction with multiple proteins, cortactin may be the critical binding partner for controlling adhesion remodeling. 115 FAK also regulates recruitment of dynamin to adhesive structures, via a direct interaction with the FAK FERM domain or an indirect interaction via a phosphorylated tyrosine residue in the C-terminus of FAK (tyrosine 925), and dynamin has been implicated in the disassembly of adhesions. 116, 117 Thus, FAK may regulate cell adhesion through changes in phosphorylation that affect interactions with different binding partners, including Src.
FAK has an important role in the organization of the extracellular matrix in tissue culture and the basement membrane in vivo. 118, 119 By regulating expression and secretion of matrix metalloproteinases, FAK also controls remodeling of the matrix after its initial organization, which enables FAK to control cell invasion. 120, 121 FAK functions in regulating the assembly of adhesive structures that mediate matrix degradation. FAK interactions with Cas are required to regulate invadosome formation in several cell types, and the subsequent degradation of the underlying extracellular matrix. 122 FAK also functions in controlling extracellular matrix degradation at focal adhesions and Cas is an important FAK-binding partner in controlling matrix degradation at these sites as well. 123 FAK is implicated in controlling cell proliferation and degradation of the extracellular matrix in response to mechanical signals generated by stiff matrices. [124] [125] [126] Although FAK's role in controlling cell/extracellular matrix adhesion was not surprising, the finding that FAK has a role in controlling cell-cell adhesions was unexpected. FAK is required for efficient assembly of N-cadherin-and E-cadherin-mediated cell/ cell adhesions and FAK-dependent control of the activity of Rho family proteins appears responsible for modulating the assembly of cell/cell junctions. 127, 128 Impairment of FAK activity also retards the disassembly of cell/cell junctions in response to stimuli that promote epithelial to mesenchymal transition. 129 Thus, FAK is implicated in controlling both the assembly and disassembly of different classes of cell adhesions.
Mouse models and human disease FAK is essential for mouse development, as demonstrated by the embryonic lethal phenotype of FAK-null mice. 130 These embryos exhibit defects in mesoderm development, neural tube closure and heart tube formation. 131 The analysis of conditional knockout mice has provided additional insight into FAK's role in development. These include essential roles in embryonic angiogenesis, 132, 133 development of the heart/aorta 134 and differentiation of neural crest cells. 135 Further, in mouse models FAK has also been implicated in the regulation of axonal branching, 136 myelination 137 and mammary gland development during pregnancy. 138 As outlined below, FAK is implicated in a number of human diseases. Thus, FAK appears to have an important role in regulating cell adhesion, cell-cell interactions and cell survival, all of which are altered in Src-transformed cells and in human cancer.
P120-CATENIN, P120CTN, P120
Interest in p120 was initially based on the profiling of tyrosinephosphorylated proteins in cells expressing activated forms of Src that were either transformation-competent or transformationdefective. Remarkably, p120 was unique among the substrates in that its phosphorylation correlated with cell transformation, suggesting a possible role in the mechanism of transformation. 53 
Structure
Most of the substrates emerged as unique regulators of the actin cytoskeleton, each possessing one or more domains typically associated with PTK signaling. In contrast, p120 contained tandem armadillo repeats with weak homology to the Armadillo repeats in b-catenin/Armadillo. 139, 140 Further analysis revealed sets of tandem repeats in p120 and several other proteins, leading to the recognition and naming of the Armadillo Repeat Domain, a structure that has emerged over the last decade as an important protein-protein interaction scaffold. Notably, the similarity to bcatenin led to testing for an analogous interaction with classical cadherins. It turned out that p120 and b-catenin interact simultaneously with adjacent motifs in the cadherin cytoplasmic tail. 141 Because of these molecular interactions, p120 was originally called 'Cas' for cadherin-associated (Src) substrate. 142 That name was soon rescinded in favor of p120-catenin (p120) 143 to avoid being confused with the previously described Src substrate p130Cas. 54 Cellular function and effects of phosphorylation The catenin identifier turned out to be a highly accurate descriptor, as p120 and b-catenin are direct stoichiometric binding partners for each of the 26 classical cadherins, important mediators of cell-cell adhesion in solid tissues. b-catenin interacts further with a-catenin, a vinculin-like actin-binding protein at the dynamic functional interface between the cadherin cytoplasmic tail and the underlying actin cytoskeleton. The term catenin (that is, chain or to link), coined well before the discovery of p120, was aimed originally at the a-catenin/b-catenin partnership. However, p120 also modulates the actin interface, albeit via direct and/or indirect regulation of Rho GTPases. For example, cytoplasmic p120 functions as a guanine nucleotide dissociation inhibitor, binding RhoA and blocking its activity by preventing GTP/GDP exchange. 144, 145 Cadherin-bound p120, on the other hand, does not bind RhoA directly, 144 but instead recruits factors such as p190RhoGAP [146] [147] [148] and ROCK 149 that in turn localize RhoA activity to adherens junctions. Hence, p120 and b-catenin are important regulators of the actin cytoskeleton and participate actively in the global integration of cytoskeletal activity.
More recently, p120 has emerged as a master regulator of classical cadherin stability and cell surface retention. p120 modulates the strength of cell-cell adhesion, in part, by controlling cadherin levels. Nascent cadherin complexes arrive at the cell surface independent of p120. Thereafter, direct interaction with p120 is essential as the complex is otherwise rapidly internalized and degraded. Thus, loss of p120 in most adhesive cell types results in reduced or complete loss of cell-cell adhesion. Mechanistically, p120 prevents cadherin endocytosis by physically masking crucial endocytic signals in the cadherin juxtamembrane domain. 150 Recent evidence suggests a second role, however, as the cell fate and endocytic adaptor protein Numb can regulate endocytosis of the entire cadherin complex (p120 included) through direct interaction with p120. 151 Transformation by Src in many cell types is associated with disruption of adherens junctions, actin-based cell-cell adhesion complexes organized by classical cadherins. p120 is also tyrosinephosphorylated by various growth factor receptors, including the EGF, PDGF and CSF-1 receptors, 152, 153 which are functionally coupled to cadherins by poorly understood mechanisms. 154 The role of p120 phosphorylation in these processes is not yet known. p120 itself, on the other hand, is clearly essential for transformation by Src and Rac1, but not H-Ras, it remains an open question, therefore, as to whether tyrosine phosphorylation of p120 in fact has an essential role in transformation.
Mouse models and human disease The in vitro effects of p120 loss are also observed in vivo in mouse models, although the complexity of the phenotypes varies depending on the epithelial organ targeted. Global p120 knockout is early embryonic lethal (Bday 9.5). Targeted deletion in the intestinal epithelium causes cell-cell adhesion defects and serious intestinal bleeding, leading to inflammation and death in the first three weeks of life. 155 Curiously, p120 ablation on a very limited basis (that is, B10% of the intestinal epithelial surface) by itself induces intestinal tumors in about half of the mice, but tumors invariably retain at least one p120 allele. 156 In the squamous epithelia of skin and esophagus, p120 induces an apparently cell autonomous inflammatory response (that is, it cannot be attributed to a barrier defect). 157, 158 These clues suggest an as yet poorly understood role for p120 in the innate immune system. The esophageal phenotype involves progression to esophageal cancer that closely resembles the human condition. In contrast, the mammary gland does not form at all in the absence of p120, 159 and the salivary gland displays misshapen ducts that lack acini. 160 Remarkably, the epithelium of the prostate is not noticeably affected, 159 and is the only system to date lacking an obvious phenotype. Despite significant tissue-specific variation, the mouse models in general illustrate multiple connections to cancer and will ultimately be essential for understanding the roles of p120 misexpression in human cancer. Indeed, the human pathology literature reveals frequent mislocalization and/or downregulation of p120 in most epithelial cancers. 161 The mechanism(s) of p120 dysregulation in human cancer are not yet clear but the involvement of receptor-and Src-family tyrosine kinases remain a strong possibility.
PHARMACEUTICAL TARGETING OF SRC AND ITS SUBSTRATES
Among the substrates identified in this study, FAK, as well as Src, appear to have the greatest promise as druggable targets for the treatment of cancer. The approach to identify new signaling pathway components remains an important element in the discovery of targets for pharmaceutical development. However, the lengthy path from target identification to drug registration shifted the effort toward later stages of preclinical development. Companies save time and money if their starting point involves a preclinically, well-validated target before initiating a drug hunting campaign. [162] [163] [164] For these reasons, drug targeting of Src and its substrates proves a critical opportunity for the discovery and development of new therapies for cancer and other diseases. There have been significant strides in developing novel therapies inhibiting Src. 165, 166 However, the pharmaceutical industry should explore new avenues of target discovery to ensure future development of highly effective treatments. Targeting Src substrates represents a rational next step toward the deliberate intervention of this key signaling cascade in multiple disease states.
To date, four small-molecule inhibitors of Src have been developed for treatment of various malignancies, including chronic myelogenous leukemia (CML). 165, 166 Among these, dasatinib (Sprycel) and bosutinib (Bosulif) exhibit low nanomolar activity against Src-family kinases. 167, 168 However, they both equally inhibit Bcr-Abl kinase, the pivotal target in CML, and other tyrosineand serine/threonine-specific kinases, thereby promoting their anti-CML activity. [167] [168] [169] Three of the inhibitors are ATPcompetitive, including dasatinib, bosutinib and saracatinib, while KX-01 is peptidomimetic. 169 Additional non-selective kinase inhibitors have been developed, including nilotinib (Tasigna), that inhibit Src-family kinases amongst their off-target activities. 170 Although anti-Bcr-Abl activity has enabled dasatinib, bosutinib and nilotinib to be marketed for CML, the activity of the four Src inhibitors in clinical trials of solid tumors has been less robust. 165, 166 Src regulates tumor cell migration, invasion and adhesion in a variety of model systems, suggesting a role in tumor cell metastasis. 171, 172 In addition, Src exhibits downstream activity in both angiogenesis and bone resorption pathways, indicating functions in tumor cell maintenance and survival. 166 . Src also has roles in tumor cell proliferation and cell cycle control in both in vitro and in vivo pre-clinical models of many major solid tumor types, including prostate, breast, colon, lung, pancreatic and glioblastoma, among others. 173, 174 The pre-clinical antitumor activities of Src inhibitors provided the rationale, which prompted investigators to evaluate Src inhibitors in multiple solid tumor clinical trials. 166 Early trials show promise, leading to advanced studies evaluating combinations with chemotherapy or other targeted agents. One possibility for the limited success of Src inhibitors as single agents is their inability to induce apoptosis, potentially required for clinical antitumor activity, despite their inhibitory effects on tumor cell proliferation and xenograft growth. 173 The significant effects of Src inhibitors in tumor cell motility in vitro may impart a critical activity on patient metastases. Previous and ongoing clinical trials evaluating the effects of Src inhibitors in metastatic cancer are critical for shaping our understanding of their antitumor capacity. Evaluating early stages of malignancy such as in adjuvant settings and studying rational combinations of Src inhibitors with chemotherapy or other targeted agents is warranted. Another limitation for the success of Src inhibitors in solid tumors may be a lack of standard biomarkers. Such data could identify responsive patients, and clinical trials could focus on those patients that demonstrate a molecular response to treatment. The potential for establishing novel Src biomarkers may exist within the rich panel of Src substrates. 8 The discovery of Src substrates provided an important cornerstone in the development of agents targeting downstream effectors of Src function. 5 One key target is FAK, implicated in multiple cancer types. [175] [176] [177] [178] Similar to its upstream activator Src, FAK promotes tumor cell motility, survival and angiogenesis, thereby validating its potential utility in the clinical setting. [175] [176] [177] [178] [179] [180] Five small-molecule FAK inhibitors have been described, several having advanced into clinical trials. [181] [182] [183] Although early in development, these agents show promise for use in the armamentarium against different tumor types. Similarly as observed for Src inhibitors, perhaps the pre-clinical validation of FAK in survival and cell motility points to the potential activity of inhibitors as potent anti-metastatic agents rather than impacting primary tumors. [179] [180] [181] [182] [183] Combination therapies that address tumor de-bulking (for example, chemotherapy) with an anti-metastatic drug (for example, potentially FAK inhibitors) may have the best patient response rate and progression-free survival. Future and ongoing clinical evaluation of existing and new inhibitors should help to answer these fundamental questions.
Other substrates of Src have been studied extensively. 5, 46, 65, 68, [184] [185] [186] [187] The substrate proteins p130Cas, p120Ctn, p110-AFAP1, p85-cortactin and p210 tensin exhibit functional interactions with important partner proteins. 5, 46, 65, 68, [184] [185] [186] [187] Such interactions are crucial for their functions in tumor cell biology. Pharmaceutical intervention of protein-protein interactions emerged as a potential area for further exploration. 188, 189 Although many biological therapies are marketed based on disruption or stabilization of protein-protein interactions, the approach remains challenging for small-molecule development targeting intracellular proteins. The large surface area between protein domains and few binding pockets amenable to smallmolecule docking limits this approach. Peptide scaffolds provided the basis for generating some protein-protein interface inhibitors. 188, 189 Recently, protein-complex stabilizers that enhance the retention time of key complexes have been generated and may have therapeutic utility. 188, 189 Allosteric site modulators offer an alternative approach when targeting outside of enzymatic domains, such as those that inhibit myristate binding in the autoinhibitory pocket of the Bcr-Abl kinase. 190 A variety of potential therapeutic agents have been generated for protein interfaces that possess high affinity, but are larger than typical pharmaceuticals. 188, 189 Overall, the approach has significant merit, and the industry is poised to harvest novel medicines from the large breadth of protein-complexes involved in tumor cell biology. The Src substrates and their cognate interactions may serve as targets for pharmaceutical development, possibly by RNA interference, and as clinical biomarkers for drugs that interfere with Src-associated pathways.
Targeting Src, FAK or other substrates may provide critical new drugs for cancer treatment, but may best be served in combinations with other drugs in parallel or convergent pathways. The development of resistance is common among targeted agents, particularly with kinase inhibitors. Some mutations in kinases remain sensitive to drugs, while others are resistant, such as the T315I mutation of Bcr-Abl not inhibited by either dasatinib or bosutinib. 169 Drug combinations that include multiple Src pathway inhibitors may provide a rational approach for reducing relapse for malignancies where Src exhibits a direct role.
The discovery of the Src substrates exemplifies a 'shotgun' approach to identify multiple proteins involved in Src biology. 8 Today, microarrays, protein arrays, yeast two-hybrid systems, synthetic lethality screens and other technologies enable researchers to identify putative targets in multiple settings, including signal transduction pathways, protein networks and patient responses in clinical trials to experimental agents. Broad approaches to the discovery of critical connections between cellular proteins require exploration to enhance our understanding of the cell system beyond an individual molecular pathway. 191 Defining the system biology and understanding tumor microenvironments may hasten the clinical application of appropriate combinations of new medicines customized for each patient.
SUMMARY
Twenty years of study has provided much information about the structure and function of Src substrates. The work highlighted herein was among the first to describe an important group of Src substrates involved in the regulation of cell adhesion and actin dynamics (Figure 1) . Notably, the main roadblock from outset had little to do with the technical challenges. Indeed, by 1989, just 2 years into the project, both mAbs and partial cDNAs for most of the substrates were already in hand, but it was not a project for the risk averse. Although the jury is perhaps still out on p120, the substrates identified did not turn out to be essential for transformation. They were, however, among the first bona fide Src substrates identified, and taught us a great deal about Src and its substrates. Two decades later, the original goals of the project seem rather unimportant compared to the enormous impact of many of the substrates in areas that could not have been anticipated a priori.
Driven by a compelling question, application of novel technologies, and the willingness to invest time and energy in a 'risky' venture, we began the search for the Src substrates. In today's difficult funding environment, we must consider whether this type of scientific effort will garner support. The substantial effort to identify and characterize Src substrates involved not only the authors of this review, but a number of post-doctoral fellows, graduate students and technicians. Importantly, the rewards have been notable. A survey of PubMed citations lists over 6000 papers on these substrates discussed above. Understanding the function of these proteins far exceeded the original goal of understanding how Src functions to transform cells and has in addition provided novel insights as to how these proteins contribute to the complex regulation of cellular dynamics. Figure 1 . The five substrates identified during the course of this study largely regulated cytoskeletal processes that are affected by Srctransformation. P120CTN regulates E-cadherin interactions between cells, p85-cortactin regulates invadopodia formation and actin polymerization, p110-AFAP1 regulates actin filament cross-linking, p125FAK and p130Cas regulate cell adhesion complexes.
